This week, the ratings of 3 Life Sciences Tools & Services stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Albany Molecular Research, Inc.’s (AMRI) rating worsens to a F from the company’s D rating a week ago. Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States, Europe, and Asia. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMRI stock.

Harvard Bioscience, Inc. (HBIO) is having a tough week. The company’s rating falls from a D to a F. Harvard Bioscience, Inc. develops, manufactures, and markets tools used in drug discovery research and pharmaceutical and biotechnology companies, universities, and government laboratories. The company also gets F’s in operating margin growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HBIO stock.

This is a rough week for Bioanalytical Systems, Inc. (BASI). The company’s rating falls to D from the previous week’s C. Bioanalytical Systems, Inc. provides contract drug development services and research equipment to many global pharmaceutical, medical research and biotechnology companies and institutions. The company also gets F’s in operating margin growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of BASI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.